Loading patent…
AssigneeEmory University
InventorsKathy P. Parker, David B. Rye, Andrew Jenkins
Estimating the term…
GABAA receptor mediated hypersomnia can be treated by administering a GABAA receptor antagonist (e.g., flumazenil; clarithromycin; picrotoxin; bicuculline; cicutoxin; and oenanthotoxin). In some embodiments, the GABAA receptor antagonist is flumazenil or clarithromycin. The GABAA receptor mediated hypersomnia includes shift work sleep disorder, obstructive sleep apnea/hypopnea syndrome, narcolepsy, excessive sleepiness, hypersomnia (e.g., idiopathic hypersomnia; recurrent hypersomnia; endozepine related recurrent stupor; and amphetamine resistant hypersomnia), and excessive sleepiness associated with shift work sleep disorder, obstructive sleep apnea/hypopnea syndrome, and hypersomnia (e.g., idiopathic hypersomnia; recurrent hypersomnia; endozepine related recurrent stupor; and amphetamine resistant hypersomnia.
A method of treating hypersomnia, the method comprising administering an effective amount of a GABAA receptor antagonist to a subject having hypersomnia, wherein the GABAA receptor antagonist is administered transmucosally or transdermally, and wherein the GABAA receptor antagonist is selected from the group consisting of flumazenil, clarithromycin, picrotoxin, bicuculline, cicutoxin, and oenanthotoxin.
A method of treating hypersomnia in a human subject, the method comprising administering an effective amount of a GABAA receptor antagonist to the human subject, wherein the GABAA receptor antagonist is administered transdermally, transmucosally, sublingually, or subdermally, wherein the GABAA receptor antagonist is selected from the group consisting of flumazenil, clarithromycin, picrotoxin, bicuculline, cicutoxin, and oenanthotoxin.
Dependencies are inferred from the claim text.